{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T14:35:01Z","timestamp":1721572501284},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T00:00:00Z","timestamp":1245974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The variant Creutzfeldt\u2013Jakob disease (vCJD) is a transmissible spongiform encephalopathy (TSE), mainly present in the UK and is associated with the ingestion of bovine products affected with bovine spongiform encephalopathy. Manufacturers of biological products must investigate the ability of their production processes to remove TSE agents. We studied the purification steps in the manufacturing process of two FVIII\/VWF concentrates (Alphanate<jats:sup>\u00ae<\/jats:sup> and Fanhdi<jats:sup>\u00ae<\/jats:sup>) in their ability to eliminate an experimental TSE\u2010model agent. Hamster scrapie strain 263K brain\u2010derived materials were spiked into samples of the solutions taken before various stages during its production: 3.5% polyethylene glycol (PEG) precipitation, heparin affinity chromatography and saline precipitation\/final filtrations. PEG precipitation and affinity chromatography were studied both as isolated and combined steps. TSE agent removal was determined using a laboratory scale model representative of the industrial manufacturing process. The prion protein (PrP<jats:sup>Sc<\/jats:sup>) was measured with Western blot and TSE infectivity was measured with bioassay. Western blot results were in agreement with those obtained by bioassay, showing a significant removal capacity in the production process: 3.21\u20133.43 log<jats:sub>10<\/jats:sub> for the PEG precipitation; about 3.45 log<jats:sub>10<\/jats:sub> for the affinity chromatography; and around 2.0 log<jats:sub>10<\/jats:sub> for the saline precipitation plus final filtrations. PEG precipitation and heparin affinity chromatography were demonstrated to be two complementary TSE\u2010model agent removal mechanisms with total removal being the sum of the two. An overall reduction factor of around 8 log<jats:sub>10<\/jats:sub> can be deduced. The tests from the production process of FVIII\/VWF complex concentrates have demonstrated their potential for eliminating TSE agents.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02067.x","type":"journal-article","created":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T07:01:54Z","timestamp":1245999714000},"page":"1249-1257","source":"Crossref","is-referenced-by-count":7,"title":["Elimination capacity of a TSE\u2010model agent in the manufacturing process of Alphanate<sup>\u00ae<\/sup>\/Fanhdi<sup>\u00ae<\/sup>, a human factor VIII\/VWF complex concentrate"],"prefix":"10.1111","volume":"15","author":[{"given":"J. M.","family":"DIEZ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"CABALLERO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"BELDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"OTEGUI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"GAJARDO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. I.","family":"JORQUERA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,26]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"National Center for Infectious Diseases.Preliminary investigation suggests BSE\u2010infected cow in Washington state was likely imported from Canada.CDC.http:\/\/www.cdc.gov\/ncidod\/diseases\/cjd\/bse_washington.htm(last accessed on 29 December 2003)."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0701.010102"},{"key":"e_1_2_7_4_2","unstructured":"Office International Des Epizooties \u2013 World animal heath situation.Number of reported cases of bovine spongiform encephalopathy (BSE) in farmed cattle worldwide (exluding the United Kingdom).http:\/\/www.oie.int\/eng\/info\/en_esbmonde.htm(last accessed on 16 January 2009)."},{"key":"e_1_2_7_5_2","unstructured":"The National Creutzfeldt\u2010Jacob Disease Surveillance Unit (NCJDSU)The University of Edingburgh.http:\/\/www.cjd.ed.ac.uk\/figures.htm(last accessed on 4 May 2009)."},{"key":"e_1_2_7_6_2","unstructured":"The National Creutzfeldt\u2010Jacob Disease Surveillance Unit (NCJDSU)The University of Edingburgh.http:\/\/www.cjd.ed.ac.uk\/vcjdworld.htm(last accessed on 16 January 2009)."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02056.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998409000.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0707.017731"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_7_15_2","unstructured":"Health Protection Agency.4th case variant CJD infection associated with blood transfusionHPA Press Statement 19 January2007.http:\/\/www.hpa.org.uk\/webw\/HPAweb&HPAwebStandard\/HPAweb_C\/1195733711457?p=1171991026241(last accessed on 28 April 2009)."},{"key":"e_1_2_7_16_2","unstructured":"Health Protection Agency vCDJ abnormal prion protein patient with haemophilia at post mortem HPA Press Statement 17 February2009.http:\/\/www.hpa.org.uk\/webw\/HPAweb&HPAwebPrinterFriendly\/HPAweb_C\/1234859690542?p=1231252394302(last accessed on 5 March 2009)."},{"key":"e_1_2_7_17_2","unstructured":"World Federation of Hemophilia Signs of variant Creutzfeldt\u2010Jakob disease in a patient with hemophilia: FVIII concentrates most likely causeWFH Safety & Supply News2009; 8.http:\/\/www.wfh.org\/index.asp?lang=EN(last accessed on 23 April 2009)."},{"key":"e_1_2_7_18_2","unstructured":"Paul\u2010Ehrlich\u2010Institut.Sicherheit von Blutprodukten hinsichtlich vCJK Post mortem\u2010Nachweis des vCJK\u2010Erregers bei einem mit Faktor VIII behandelten H\u00e4mophilen 16 March2009.http:\/\/www.pei.de\/cln_115\/nn_163078\/DE\/infos\/fachkreise\/am\u2010infos\u2010ablage\/sik\/2009\u201003\u201013\u2010vcjk\u2010haemophilipat.html(last accessed on 28 April 2009)."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615387"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00683.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00216.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01863914"},{"key":"e_1_2_7_24_2","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed LJ, and Muench H","year":"1938","journal-title":"Am J Hygiene"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040449.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(99)00135-4"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7820086.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-6892.2004.00444.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00617.x"},{"key":"e_1_2_7_30_2","volume-title":"Prion Biology and Diseases","author":"Prusiner SB.","year":"2003"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02067.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02067.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:20:18Z","timestamp":1697242818000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02067.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02067.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02067.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,26]]}}}